AllianceBernstein’s Ovid Therapeutics OVID Stock Holding History

AllianceBernstein’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$174K	Buy	+78,260	New	+$202K	﹤0.01%	3182
2025 Q2	–	Sell	-47,780	Closed	-$14.9K	–	3302
2025 Q1	$14.9K	Hold	47,780	–	–	﹤0.01%	3185
2024 Q4	$44.6K	Sell	47,780 -100	-0.2%	-$112	﹤0.01%	3193
2024 Q3	$56.5K	Hold	47,880	–	–	﹤0.01%	3184
2024 Q2	$36.8K	Buy	+47,880	New	+$133K	﹤0.01%	3205
2021 Q2	–	Sell	-56,100	Closed	-$226K	–	3388
2021 Q1	$226K	Hold	56,100	–	–	﹤0.01%	3019
2020 Q4	$130K	Hold	56,100	–	–	﹤0.01%	3077
2020 Q3	$322K	Hold	56,100	–	–	﹤0.01%	2780
2020 Q2	$413K	Buy	+56,100	New	+$262K	﹤0.01%	2727
2018 Q4	–	Sell	-11,746	Closed	-$67K	–	3131
2018 Q3	$67K	Buy	+11,746	New	+$89K	﹤0.01%	3105

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

AllianceBernstein's OVID Position: Q2 2026 in Review

AllianceBernstein opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 78,260 shares worth $174K. The stake represents ﹤0.01% of the portfolio and ranks #3182 among its holdings. This is a return to the name: AllianceBernstein previously reported a position in OVID as recently as Q1 2025.

AllianceBernstein first reported a position in OVID in Q3 2018 and has held it in 10 quarters since. The position peaked at $413K in Q2 2020. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

AllianceBernstein held 78,260 shares of Ovid Therapeutics worth $174K as of Q2 2026.
Ovid Therapeutics was a new AllianceBernstein position in Q2 2026.
Ovid Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3182 holding.
AllianceBernstein first reported a position in Ovid Therapeutics in Q3 2018 and has held it in 10 quarters since.
AllianceBernstein's Ovid Therapeutics position peaked at $413K in Q2 2020.
130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.